Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Biodistribution and Vector Shedding Assay Development for IND-Enabling Toxicology Studies

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Biodistribution and Vector Shedding Assay Development for IND-Enabling Toxicology Studies

CELL & GENE | RNA | BIOLOGICS

Successful Investigational New Drug (IND) applications for AAV-based therapeutics require robust, quantitative data on vector biodistribution and potential shedding. This page details the strategic development and validation of qPCR and NGS-based assays designed to meet global regulatory expectations for safety and toxicology programs. We cover assay design for diverse biological matrices, GxP compliance, and the integration of advanced sequencing methods to characterize vector behavior in vivo, directly supporting an accelerated 18-24 month IND timeline.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

Frequently Asked Questions (FAQ)

    What are the primary assays for biodistribution studies?

    A: The standard is quantitative PCR (qPCR) or droplet digital PCR (ddPCR) to quantify vector genome copy numbers per microgram of genomic DNA in target and non-target tissues. For gene editing payloads, advanced Next-Generation Sequencing (NGS) assays are used to identify potential off-target editing events.

    Which biological matrices are typically analyzed for shedding?

    A: Shedding analysis is performed on matrices such as urine, feces, saliva, blood, and swabs, depending on the vector, route of administration, and regulatory guidance. The goal is to assess the potential for vector transmission.

    What level of assay validation is required for IND submission?

    A: Assays supporting GxP toxicology studies must be fully validated according to regulatory guidelines. This includes establishing specificity, sensitivity, linearity, precision, accuracy, and the lower limit of quantification (LLOQ) for each matrix.

    How is non-target tissue biodistribution data used?

    A: This data informs the overall safety profile of the therapeutic. It helps regulators understand vector persistence, clearance kinetics, and potential for accumulation in tissues like the gonads or central nervous system, which have specific safety implications.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Strategic Assay Development for Regulatory Filings

Characterizing the in vivo fate of an AAV vector is a foundational component of any preclinical safety program. Regulatory bodies require a clear understanding of where the vector distributes, how long it persists in target and non-target tissues, and the potential for shedding. Developing sensitive, specific, and validated bioanalytical methods to generate this data is a primary objective for de-risking a development program.

Our approach begins with designing custom qPCR assays targeting unique sequences within the vector genome, typically the promoter or transgene cassette. These assays are then rigorously optimized for each biological matrix, accounting for potential PCR inhibitors and varying DNA extraction efficiencies. This meticulous, matrix-specific validation under GxP conditions ensures the resulting data is reliable and suitable for inclusion in an IND package.

Advanced Sequencing for Comprehensive Safety Assessment

For gene editing therapeutics, quantifying vector biodistribution is only part of the safety assessment. It is also necessary to evaluate the activity of the nuclease payload. As demonstrated in recent research, advanced methods like ITR-Seq provide a powerful tool for identifying genome-wide DNA editing sites and potential off-target nuclease activity following in vivo administration (PMID: 32183699). Incorporating such NGS-based approaches provides a deeper level of safety characterization, offering high-fidelity intelligence tracking therapeutic delivery and its potential consequences at the genomic level.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

Commitment to Animal Welfare in In Vivo Studies

Our programs are designed to support the 3Rs: Replacement, Reduction, and Refinement of animal use in research. Our >100,000 sq ft facility is fully accredited by AAALAC International and registered with the USDA, ensuring all procedures meet or exceed established guidelines.

Our scientific and veterinary staff, including experts from our strategic partners, collaborate to design study protocols that maximize data acquisition while minimizing animal stress. This approach has been integral to our clients’ success: since 2019, programs we have supported have achieved a 100% IND success rate. Franklin Biolabs as a brand launched in 2024, continuing this legacy of scientific excellence and ethical conduct.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities